Get the Stockscreener App
2.4046
2.03%
-0.0554
Acelyrin Inc stock is traded at $2.4046, with a volume of 230.69K.
It is down -2.03% in the last 24 hours and up +10.80% over the past month.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
See More
Previous Close:
$2.46
Open:
$2.47
24h Volume:
230.69K
Relative Volume:
0.13
Market Cap:
$259.83M
Revenue:
-
Net Income/Loss:
$-299.80M
P/E Ratio:
-0.8467
EPS:
-2.84
Net Cash Flow:
$-217.49M
1W Performance:
-6.23%
1M Performance:
+10.80%
6M Performance:
-59.15%
1Y Performance:
-50.61%
1-Day Range:
$2.375
$2.49
1-Week Range:
$2.34
$2.635
52-Week Range:
$1.845
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
Name
Acelyrin Inc
Sector
Industry
Phone
805-456-4393
Address
4149 LIBERTY CANYON RD., AGOURA HILLS
Compare SLRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
2.405 | 259.83M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.12 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
536.78 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
550.61 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.97 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
230.82 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-08-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Sep-13-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-05-23 | Initiated | H.C. Wainwright | Buy |
| May-30-23 | Initiated | Jefferies | Buy |
| May-30-23 | Initiated | Morgan Stanley | Overweight |
| May-30-23 | Initiated | Piper Sandler | Overweight |
| May-30-23 | Initiated | TD Cowen | Outperform |
View All
Acelyrin Inc Stock (SLRN) Latest News
ACELYRIN Encourages Stockholders to Support Merger with Alumis Inc. Following ISS Recommendation - Nasdaq
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the ... - Eagle-Tribune
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - Yahoo Finance
Acelyrin Shareholder Notice - Newsfile
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Acelyrin urges stockholders to vote for proposed merger with Alumis - Yahoo Finance
ACELYRIN urges stockholders to approve Alumis merger - Investing.com
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - The Manila Times
ACELYRIN, Inc. Urges Stockholders to Vote in Favor of Proposed Merger with Alumis Inc. Ahead of May 13, 2025 Meeting - Nasdaq
ACELYRIN Board Makes Final Push for Alumis Merger: 48% Ownership Deal at Stake in Critical May Vote - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition - TipRanks
Acelyrin (SLRN) Faces Shareholder Opposition to Alumis Merger - GuruFocus
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis - MSN
Acelyrin stock gains as Trium rebuffs M&A deal (SLRN:NASDAQ) - Seeking Alpha
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - ADVFN
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
Alumis, ACELYRIN amend proposed merger pact - MSN
Alumis And Acelyrin Announce Amended Merger Agreement - marketscreener.com
Alumis Raises Share Consideration for Acelyrin Acquisition - marketscreener.com
ACELYRIN, INC. Amends Merger Agreement with Alumis - TipRanks
ACELYRIN and Alumis Announce Revised Merger Agreement Enhancing Stockholder Ownership and Value - Nasdaq
Alumis and ACELYRIN Announce Amended Merger Agreement - The Manila Times
Alumis Secures Major Immunology Merger: $737M Cash Runway Stretches to 2027, 62% Shareholders Back Deal - Stock Titan
Wheat Pushing Higher Ahead of Export Sales Release - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders - The Malaysian Reserve
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
Best Quantum Computing Stocks to Watch in 2025 - The Globe and Mail
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - TradingView
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
Indo-Asian News Service - Indo-Asian News Service (IANS)
Acelyrin Inc Stock (SLRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acelyrin Inc Stock (SLRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Murugan Amar | Chief Legal Officer |
Mar 17 '25 |
Sale |
2.74 |
3,913 |
10,737 |
121,587 |
| Mpofu Shephard | Chief Medical Officer |
Mar 17 '25 |
Sale |
2.74 |
3,211 |
8,811 |
121,789 |
2.11%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):